Form 4: Dare Bioscience Director Gregory Matz Receives 4,500 Stock Options

Dare Bioscience, Inc. Director Gregory W. Matz was granted 4,500 stock options with an exercise price of $2.44, vesting based on continued service and potential change of control.

Summary

• Gregory W. Matz, a Director of Dare Bioscience, Inc. (DARE), was granted 4,500 stock options.
• The transaction date for this grant was July 9, 2025.
• Each stock option has an exercise price of $2.44.
• The options will vest in full on the earlier of the first anniversary of the grant date (July 9, 2026) or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date.
• Vesting is subject to Mr. Matz's continued service as a director.
• The options will become exercisable in full upon a change in control of Dare Bioscience, Inc.
• The expiration date for these options is July 9, 2035.
• Following this transaction, Mr. Matz beneficially owns 4,500 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that generally aligns management interests with shareholders, indicating a stable governance practice. It is not a major positive or negative event in itself.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• The value of the stock options is dependent on the future stock price of Dare Bioscience, Inc. exceeding the exercise price of $2.44.
• The options are subject to forfeiture if the director's service is not continued until the vesting conditions are met.
• Potential dilution for existing shareholders if the options are exercised in the future.

Future Outlook

The stock options are designed to incentivize the director's continued service and align their interests with the company's long-term performance, with vesting contingent on service and potential acceleration upon a change in control.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industry, as well as across publicly traded companies, to attract and retain talent, and to align the interests of leadership with shareholder value creation.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across various industries, including biotechnology, to incentivize performance and align interests.
• The specific number of options (4,500) and the exercise price ($2.44) would typically be benchmarked against similar-sized companies in the biotech sector or against Dare Bioscience's historical compensation practices for its directors. Without further context on the company's market capitalization, stage of development, or other director compensation packages, a detailed comparison is limited, but the mechanism itself is standard.

Corporate Governance

Related Party Transactions

• The grant of stock options to Gregory W. Matz, a Director of Dare Bioscience, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefits from increased alignment of director's interests with company performance.
• Employees: No direct impact mentioned, but general compensation practices can influence overall company culture and talent retention.

Next Steps

• The options will vest based on the specified conditions (continued service or annual meeting).
• The director may exercise the options at any time after vesting and before the expiration date, provided the stock price is above the exercise price.

Key Dates

Recommendation

Keywords

Dare Bioscience, DARE, stock option, insider transaction, director compensation, equity grant, Form 4, Gregory Matz